Could a simple heart pill boost lung cancer treatment?
NCT ID NCT05387512
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked back at medical records of 60 people with advanced non-small cell lung cancer who received standard immunotherapy (anti-PD-1/PD-L1 drugs). Researchers checked whether those who also took beta-blockers (commonly used for heart conditions) had different outcomes, like how long the cancer stayed under control. The goal is to see if this common heart medication might influence how well immunotherapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
beta-blocker (concomitant exposure during anti-PD-1/PD-L1 therapy)
What this could lead to
If beta-blockers are linked to better outcomes, this could point toward a simple, low-cost way to boost immunotherapy effectiveness in lung cancer.
What could go wrong
This is a small, retrospective observational study, not a controlled trial. It can only show an association, not cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Pharmacy, Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226000, China